Literature DB >> 10948138

Regulation of cytokine expression in mice immunized with cryptococcal polysaccharide, a glucuronoxylomannan (GXM), associated with peritoneal antigen-presenting cells (APC): requirements for GXM, APC activation, and interleukin-12.

R Blackstock1, N McElwee, E Neller, J Shaddix-White.   

Abstract

Mice immunized with peritoneal exudate cells (PEC; used as antigen-presenting cells [APC]) that are pulsed ex vivo with cryptococcal capsular polysaccharide, a glucuronoxylomannan (GXM), exhibit increased survival times and delayed-type hypersensitivity reactions when they are infected with Cryptococcus neoformans. These responses are GXM specific. The present study revealed that GXM-APC immunization enhanced development of anticryptococcal type-1 cytokine responses (interleukin-2 [IL-2] and gamma interferon) in mice infected with C. neoformans. The enhancement was not GXM specific, because immunization with GXM-APC and immunization with APC alone had similar effects. GXM-APC (or APC) immunization caused small increases in the expression of type-2 cytokines (IL-4 and IL-5), but the increases were not always statistically significant. IL-10 levels were not regulated by immunization with GXM-APC or APC. GXM-APC prepared with PEC harvested from mice injected with complete Freund's adjuvant (CFA) enhanced type-1 cytokine responses, while GXM-APC prepared with PEC induced with incomplete Freund's adjuvant were ineffective. The CFA-induced PEC had an activated phenotype characterized by increased numbers of F4/80(+) cells that expressed CD40, B7-1, and B7-2 on their membranes. The immunomodulatory activity of the CFA-induced APC population was not attributed to their production of IL-12 because GXM-APC prepared with peritoneal cells harvested from IL-12 knockout mice or their wild-type counterparts were equally effective in augmenting the type-1 response. Blocking of IL-12 in the recipients of GXM-APC early after APC infusion revealed that early induction of IL-12 secretion was not responsible for the immunomodulatory response elicited by GXM-APC. These data, considered together with previously reported data, reveal that the protective activity of GXM-APC immunization involves both antigen-specific and nonspecific activities of GXM-APC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10948138      PMCID: PMC101763          DOI: 10.1128/IAI.68.9.5146-5153.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  NK cell triggering by the human costimulatory molecules CD80 and CD86.

Authors:  J L Wilson; J Charo; A Martín-Fontecha; P Dellabona; G Casorati; B J Chambers; R Kiessling; M T Bejarano; H G Ljunggren
Journal:  J Immunol       Date:  1999-10-15       Impact factor: 5.422

2.  Expression of surface antigens during the differentiation of human dendritic cells vs macrophages from blood monocytes in vitro.

Authors:  A D Santin; P L Hermonat; A Ravaggi; M Chiriva-Internati; M J Cannon; J C Hiserodt; S Pecorelli; G P Parham
Journal:  Immunobiology       Date:  1999-06       Impact factor: 3.144

3.  Triggering of murine NK cells by CD40 and CD86 (B7-2).

Authors:  A Martín-Fontecha; E Assarsson; E Carbone; K Kärre; H G Ljunggren
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

4.  Agglutinin from Limulus polyphemus. Purification with formalinized horse erythrocytes as the affinity adsorbent.

Authors:  T P Nowak; S H Barondes
Journal:  Biochim Biophys Acta       Date:  1975-05-30

Review 5.  CD40 and CD154 in cell-mediated immunity.

Authors:  I S Grewal; R A Flavell
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

6.  IL-18 protects mice against pulmonary and disseminated infection with Cryptococcus neoformans by inducing IFN-gamma production.

Authors:  K Kawakami; M H Qureshi; T Zhang; H Okamura; M Kurimoto; A Saito
Journal:  J Immunol       Date:  1997-12-01       Impact factor: 5.422

7.  Differential regulation of immune responses by highly and weakly virulent Cryptococcus neoformans isolates.

Authors:  R Blackstock; K L Buchanan; A M Adesina; J W Murphy
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

8.  Non-specific immunosuppression by Cryptococcus neoformans infection.

Authors:  R Blackstock; N K Hall
Journal:  Mycopathologia       Date:  1984-04-30       Impact factor: 2.574

9.  Modification of macrophage phagocytosis in murine cryptococcosis.

Authors:  M A Morgan; R A Blackstock; G S Bulmer; N K Hall
Journal:  Infect Immun       Date:  1983-05       Impact factor: 3.441

10.  Suppression of responses to cryptococcal antigen in murine cryptococcosis.

Authors:  B E Robinson; N K Hall; G S Bulmer; R Blackstock
Journal:  Mycopathologia       Date:  1982-12-27       Impact factor: 2.574

View more
  3 in total

1.  Roles for CD40, B7 and major histocompatibility complex in induction of enhanced immunity by cryptococcal polysaccharide-pulsed antigen-presenting cells.

Authors:  Rebecca Blackstock
Journal:  Immunology       Date:  2003-02       Impact factor: 7.397

Review 2.  The capsule of the fungal pathogen Cryptococcus neoformans.

Authors:  Oscar Zaragoza; Marcio L Rodrigues; Magdia De Jesus; Susana Frases; Ekaterina Dadachova; Arturo Casadevall
Journal:  Adv Appl Microbiol       Date:  2009       Impact factor: 5.086

3.  Involvement of the capsular GalXM-induced IL-17 cytokine in the control of Cryptococcus neoformans infection.

Authors:  Isabel Ferreira LaRocque-de-Freitas; Juliana Dutra B Rocha; Marise Pinheiro Nunes; Priscila Angelica V Oliveira; Danielle de Oliveira Nascimento; Leonardo Freire-de-Lima; Christina Maeda Takiya; Alexandre Morrot; Debora Decote-Ricardo; Jose Osvaldo Previato; George A DosReis; Lucia Mendonça-Previato; Celio Geraldo Freire-de-Lima
Journal:  Sci Rep       Date:  2018-11-06       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.